

1 **SAMP: Identifying Antimicrobial Peptides by an Ensemble Learning Model Based on**
2 **Proportionalized Split Amino Acid Composition**

3

4 Junxi Feng^{1†}, Mengtao Sun^{2†}, Cong Liu³, Weiwei Zhang⁴, Changmou Xu⁵, Jieqiong Wang⁶,
5 Guangshun Wang⁴, Shibiao Wan^{2*}

6

7 ¹ Department of Biostatistics, Harvard School of Public Health, Boston, MA, United States,
8 02115

9 ² Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center,
10 Omaha, NE, United States, 68198

11 ³ Department of Mathematics, Data Science, University of Waterloo, Waterloo, ON, Canada,
12 N2L3G1

13 ⁴ Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical
14 Center, Omaha, NE, United States, 68198

15 ⁵ Department of Food Science and Human Nutrition, University of Illinois Urbana-Champaign,
16 Urbana, IL, United States, 61801

17 ⁶ Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE,
18 United States, 68198

19 [†]These authors contributed equally to this work, and they should be regarded as co-first author.

20 *Corresponding contact: Dr. Shibiao Wan, swan@unmc.edu

21 **Abstract**

22 It is projected that 10 million deaths could be attributed to drug-resistant bacteria infections in
23 2050. To address this concern, identifying new-generation antibiotics is an effective way.
24 Antimicrobial peptides (AMPs), a class of innate immune effectors, have received significant
25 attention for their capacity to eliminate drug-resistant pathogens, including viruses, bacteria, and
26 fungi. Recent years have witnessed widespread applications of computational methods
27 especially machine learning (ML) and deep learning (DL) for discovering AMPs. However,
28 existing methods only use features including compositional, physiochemical, and structural
29 properties of peptides, which cannot fully capture sequence information from AMPs. Here, we
30 present SAMP, an ensemble random projection (RP) based computational model that leverages a
31 new type of features called Proportionalized Split Amino Acid Composition (PSAAC) in
32 addition to conventional sequence-based features for AMP prediction. With this new feature set,
33 SAMP captures the residue patterns like sorting signals at around both the N-terminus and the C-
34 terminus, while also retaining the sequence order information from the middle peptide fragments.
35 Benchmarking tests on different balanced and imbalanced datasets demonstrate that SAMP
36 consistently outperforms existing state-of-the-art methods, such as iAMPpred and AMPScanner
37 V2, in terms of accuracy, MCC, G-measure and F1-score. In addition, by leveraging an ensemble
38 RP architecture, SAMP is scalable to processing large-scale AMP identification with further
39 performance improvement, compared to those models without RP. To facilitate the use of
40 SAMP, we have developed a Python package freely available at <https://github.com/wan->
41 mlab/SAMP.

42

43 **Keywords:** Antimicrobial peptides; Proportionalized split amino acid composition; Random
44 projection; Ensemble learning; SAMP.

45

46 **Introduction**

47 Between the period of 1940s and 1960s, one of the greatest breakthroughs was the
48 development of antibiotics [1], a remarkable medication that has saved thousands of lives by
49 defeating various infectious diseases [2–6]. However, the long-term and rapid increase of
50 antibiotic use for disease treatment in large populations has resulted in the emergence of drug
51 resistance in pathogens [7–11]. The Centers for Disease Control and Prevention (CDC) has
52 reported that drug-resistant bacteria caused around 2.8 million infections and more than 35000
53 deaths in the United States [12]. According to the World Health Organization (WHO),
54 approximately 700,000 patients worldwide die from drug-resistant bacterial infections every year,
55 and the total number of deaths is predicted to increase to 10 million by 2050 [13], making it an
56 urgent challenge in the healthcare system [14,15]. Therefore, expanding a large range of new
57 antimicrobial agents to fight against pathogens is essential to relieve the huge burden of global
58 health [16].

59 Antimicrobial peptides (AMPs) are amino-acid-based oligomers or polymers, naturally
60 widespread in all forms of life, such as bacteria, animals, and plants [17–19]. They have played
61 an important role in protecting organisms from infectious diseases for millions of years, serving
62 as the first line of defense against pathogens through interrupting pathogen-associated molecular
63 processes in the innate immune system [20–24]. It has been suggested as excellent candidates for
64 developing a new generation of antibiotics due to their special ability to kill multi-resistant
65 microorganisms, including bacteria, fungi, parasites, and viruses [25–29]. In addition, substantial

66 evidence indicates that AMPs can recruit immature phagocytic and dendritic cells, leading to the
67 destruction of cancer cells and healing wounds in certain areas [24,30]. Cationic and
68 hydrophobic residues are two main characteristics of linear AMPs, enabling sequences to fold
69 into amphipathic secondary structures which tend to disrupt negatively charged membranes of
70 pathogens while sparing the healthy eukaryotic cells. Moreover, the enrichment of cholesterol
71 and neutral phospholipids in membranes also makes eukaryotic cells much less susceptible to
72 AMPs [31,32]. The main mechanism of AMPs' action is to form pores and micellization in cell
73 membranes or directly cause osmotic shock when present in high concentration [33,34].
74 Additionally, binding to specific cytosolic macromolecules is another way of AMPs to inhibit the
75 synthesis process of the cell wall or ribosomes [35,36]. Hence, AMPs can interact with many
76 different components of bacteria for multiple hits, while traditional antibiotics are typically
77 designed to target one specific enzyme. The broad interactions of AMPs make it difficult for
78 bacteria to develop resistance in a short time [37–39].

79 Natural AMPs discovery typically relies on traditional time-consuming and labor-intensive
80 wet experiments, resulting in low efficiency. Therefore, to find natural AMPs in a more efficient
81 and convenient way, it is necessary to develop in-silico predictive models to identify possible
82 AMP candidates prior to synthesis and wet lab testing. In the past decade, numerous
83 computational models based on various algorithms, such as support vector machine (SVM) [40],
84 random forest (RF) [41] and logistic regression (LR) [42], have been introduced to identify
85 peptides [43]. Most recently, Huang et al. [44] constructed a sequential model ensemble pipeline
86 (SMEP) consisting of multiple steps, including empirical selection, classification, ranking,
87 regression, and wet-lab validation. Algorithms, like boosting method (XGBoost) [45], RF as well
88 as deep learning such as the convolutional neural network (CNN) [46] and the long short-term

89 memory (LSTM) [47], were applied in different modules. With SMEP, a series of potent AMPs
90 from the entire search space of peptide libraries were identified accurately within a short period
91 of time. In another study [48], multiple natural language processing neural network models,
92 including LSTM layer, Attention layer and Encoder Representations from Transformers (BERT)
93 [49], were combined to form a unified pipeline which has been used to mine functional peptides
94 from metagenome data for in-depth investigations. Based on the algorithms applied in the
95 prediction models, they can be divided into two main categories. Models in the first category are
96 based on the deep learning (DL) architectures, like AMPScanner V2 [50] and Deep-AmPEP30
97 [51]. AMPScanner V2 applied deep neural networks (DNN) [52] with convolutional, maximal
98 pooling and LSTM layers for AMPs prediction. Deep-AmPEP30 based on convolutional neural
99 network (CNN) with two convolutional layers, two maximum pooling layers, and one fully
100 connected hidden layer to identify specifically short length AMPs which contain fewer than 20
101 amino acids. As for the second category of models, conventional machine learning (ML)
102 algorithms are generally exploited, such as iAMPpred [53] which used SVM to classify positive
103 or negative peptides. Previous studies [54] indicated that DL models did not always outperform
104 conventional ML models due to the modeling complexities and/or modeling overfitting during
105 the process of DL model construction based on training limited AMPs. Therefore, DL models are
106 not necessarily the most suitable approach for AMPs identification [54]. Nonetheless, no matter
107 the ML or DL based methods, existing computational methods rely primarily on features derived
108 from the composition, physicochemical and structural features of the peptide sequence. These
109 features may not be sufficient to fully express the rich information contained in antimicrobial
110 peptides and there is still considerable room for enhancing accuracy of AMP prediction.

111 To address the aforementioned concerns, we propose herein an ensemble random projection
112 (RP) [55] based computational model named SAMP, for which we develop a new type of
113 features called proportionalized split amino acid composition (PSAAC) [56] in addition to
114 conventional sequence-based features to improve the prediction performance of AMP
115 identification. Residue patterns such as sorting signals at around both the N-terminus and the C-
116 terminus could be captured by SAMP by using this enhanced feature set, while also remaining
117 the sequence order information extracted from the middle region fragments. Meanwhile, we
118 demonstrate that SAMP outperforms existing state-of-the-art methods in terms of accuracy,
119 Matthews correlation coefficient (MCC), the geometric mean of recall and precision (G-measure)
120 and F1-score, including iAMPpred and AMPScanner V2, when benchmarking on both balanced
121 and imbalanced datasets from different natural peptide groups, including humans, bacteria,
122 amphibians and plants. Furthermore, we integrate an ensemble RP architecture into SAMP to
123 strengthen the ability of handling large-scale AMP screening while achieving enhanced
124 performance compared to those without RP. We believe SAMP will play a significant role in
125 AMP identification, complementary to existing AMP identification approaches.

126

127 **Materials and Methods**

128 **Datasets**

129 The positive data set for natural AMPs was accumulated in the antimicrobial peptide
130 database in the past 20 years [57,58]. The negative data set was extracted from UniProt by
131 excluding peptides/proteins annotated with key words such as “antimicrobial”, “antibacterial”,
132 “antiviral”, and “antifungal” [59]. To benchmark the performance of SAMP and other state-of-
133 the-art approaches, we selected two sets of training data reported in the literature. As many

134 existing approaches only provide web servers which have already been trained in different
135 training data, to make a fair comparison, we will compare SAMP with those approaches based
136 on the same training dataset based on which the corresponding web servers were trained.
137 Specifically, the first set consists of 984 positive and 984 negative antimicrobial peptide
138 sequences obtained from [53]. This set is used to train our model and compare our proposed
139 model SAMP with iAMPpred (**Fig. 1A**). The second set consists of 2021 positive and 2021
140 negative antimicrobial peptide sequences from [50], as shown in **Fig. 1B**. This set is used to train
141 our model and compare SAMP with AMPScanner V2 [50].

142 In addition, independent testing data were collected from the dbAMP database [60],
143 containing AMP and non-AMP sequences (**Fig. 1C**). Specifically, we chose the AMP and non-
144 AMP datasets across four different species: plants, bacteria, amphibians, and humans, which
145 were originally collected in the APD [57,58] database. Given the varying peptide sequence
146 length distributions of our AMP datasets (**Figs. 1A-C**), we filtered out sequences shorter than 10
147 amino acids and longer than 500 amino acids. The sequences containing non-standard amino
148 acids were also removed. In the dbAMP benchmark dataset (**Fig. 1D-E**), in total, there are 1089
149 AMPs and 9732 non-AMPs. As found in the APD database, amphibians predominantly
150 constitute the natural AMP sequences, while bacteria form the majority in the non-AMP
151 sequences. Specifically, for the AMPs (**Fig. 1D**) of the dbAMP dataset, around half are
152 amphibian, one third belong to plant, and one fifth are bacteria. On the contrary, in the non-AMP
153 cases (**Fig. 1D**), amphibian sequences account for only 10%, and half of them are bacteria.
154 Interestingly, human sequences constitute less than 10% in both AMPs and non-AMPs (**Figs.**
155 **1D-E**). While for the amino acid sequence length distribution (**Figs. 1F-I**), most AMPs for all
156 species are with shorter amino acid sequences compared to non-AMPs, suggesting significantly

157 different sequence distributions between AMPs and non-AMPs. However, it is unlikely to use
158 the length of peptide sequences to determine whether a peptide is an AMP or non-AMP, given
159 that a significant portion of AMPs are also overlapped with non-AMPs, especially for bacteria,
160 human, and plant (**Figs. 1F-I**).

161

162 **Fig. 1 Peptide sequence distribution of AMPs and non-AMPs in benchmarking datasets.**
163 **(A-C)** The peptide sequence distribution of AMPs and non-AMPs collected from the iAMPpred
164 dataset (**A**), the AMPScanner V2 dataset (**B**) and the dbAMP dataset (**C**), respectively. **(D-E)**
165 Species breakdowns of AMPs (**D**) and non-AMPs (**E**) in the dbAMP dataset. **(F-I)** Species-
166 specific peptide sequence distribution of AMPs and non-AMPs in the dbAMP dataset, including
167 amphibian (**F**), bacteria (**G**), human (**H**) and plant (**I**).

168

169 **Feature extraction**

170 **Conventional features**

171 First, we embedded the string of peptide sequences into categories of numeric feature
172 vectors similar to those proposed in [53], which includes amino acid sequence compositional
173 features and physio-chemical (PHYC) features. The compositional features include amino acid
174 composition (AAC), pseudo amino acid composition (PAAC), and normalized amino acid
175 composition (NAAC). The PHYC features consider the hydrophobicity, net-charge, and iso-
176 electric point of peptide sequences, and were calculated using the ‘Peptide’ package [61] in R.

177

178 **Proportionalized split amino acid composition (PSAAC)**

179 In addition, to maximally extract peptide sequence information, we propose a new
180 compositional feature called proportionalized split amino acid composition (PSAAC). This
181 concept refines the split amino acid composition (SAAC) approach, which differentiates between
182 the amino acid compositions at the N and C-terminus of protein sequences [62,63]. PSAAC
183 adapts this concept specifically for peptide sequences, dividing them into distinct segments
184 according to proportions defined by the users. Given a peptide sequence \mathcal{P} of length L , we split
185 it into 3 segments using proportions (or percentage) p_1 , p_2 and p_3 , where p_1 , p_2 and p_3 represent
186 the proportion of amino acid segments for the N-terminus region, the middle region and the C-
187 terminus region, respectively, and $p_1 + p_2 + p_3 = 1$. The lengths of these segments, L_1 , L_2 ,
188 and L_3 , are:

$$L_1 = [L \times p_1] \quad (1)$$

$$L_2 = [L \times p_2] \quad (2)$$

$$L_3 = L - L_1 - L_2 \quad (3)$$

189
190 The segments are:

$$l_1 = \mathcal{P}[1:L_1] \quad (4)$$

$$l_2 = \mathcal{P}[L_1:(L_1 + L_2)] \quad (5)$$

$$l_3 = \mathcal{P}[(L_1 + L_2 + 1):L] \quad (6)$$

191
192 Now, let \mathfrak{A} be the set of 20 standard amino acids. The amino acid composition (AAC) in segment
193 l_i for $X \in \mathfrak{A}$ is given by:

$$AAC_{i,X} = \frac{\text{Count of } X \text{ in } l_i}{L} \quad (i = 1, 2, 3) \quad (7)$$

194 Note that the count of the X in each segment was divided by the whole length of the peptide
195 sequence. Then, the proportionalized split amino acid composition (PSAAC) is:

$$PSAAC_{i,X} = [AAC_{1,A}, AAC_{1,C}, \dots, AAC_{1,Y}, AAC_{2,A}, \dots, AAC_{3,Y}] \quad (8)$$

196
197
198 Previous studies [64,65] have reported that some sorting signals exist in the short segments
199 of amino acid sequences around the N-terminus, representing special information of amino acid

200 composition. In other words, different regions of a protein sequence can provide extra
201 information. For example, some specific regions may form structural domains that determine the
202 function of proteins, such as binding sites for other molecules, active sites for enzymes, or
203 domains for protein-protein interaction [65]. The PSAAC feature captures the residue patterns
204 around both the N-terminus region and the C-terminus region, while also retaining the sequence
205 order information from the middle region. Based on peptide sequences from [50], the amino acid
206 compositions for each segment (e.g., the N-terminus region, the C-terminus region, and the
207 middle region) were calculated respectively. Non-standard amino acid residues are ignored. As
208 shown in **Fig. 2**, Leucine and Glycine are the most abundant amino acids in AMPs as found
209 originally in the APD, and non-AMPs dataset respectively (**Figs. 2A-B**). There are obvious
210 differences in the composition of each amino acid at the N-terminus, the C-terminus and middle
211 region for both datasets (**Figs. 2C-D**). In the non-AMPs dataset, the least abundant amino acids
212 are Tyrosine, Methionine and Tryptophan at the N-terminus, middle region, and the C-terminus
213 respectively. Conversely, Leucine is the most abundant in all three segments. For the AMPs
214 dataset, Glycine is the most abundant at both the N-terminus and the middle region, while Lysine
215 is the most abundant at the C-terminus. The amino acids with the lowest content in the AMPs
216 dataset are Histidine at the N-terminus, Methionine in the middle region, and Tryptophan at the
217 C-terminus. Then, all the features are scaled by subtracting the mean from each column and
218 dividing it by the standard deviation. For the data collected from AMPScanner V2 and dbAMP,
219 the amino acid distribution at the N-terminus, the C-terminus and middle region is also
220 investigated and shown in **Supplementary Figs. S1-S2**. For each peptide sequence, the PSAAC
221 feature will be generated with 60 dimensions. We note that p_1 , p_2 and p_3 are user-defined

222 hyperparameters that allow flexible sequence context extraction and the number of splits can also
223 be customized, and we used three splits because of its prominent performance.

224

225 **Fig. 2 Amino acid distribution in AMPs and non-AMPs datasets based on the dataset**
226 **collected from iAMPpred.** Amino acid distribution of all sequences in **(A)** AMPs and **(B)** non-
227 AMPs dataset. Distribution of amino acid sequences in the N-terminus region, the middle region
228 and the C-terminus region of **(C)** AMPs Dataset and **(D)** non-AMPs dataset.

229

230 **Random projection**

231 Random projection (RP) is a dimension reduction technique proposed based on the
232 Johnson-Lindenstrauss lemma [66]. For our experimental analysis, we used the Gaussian random
233 matrix as our random projection matrix, which is generated from the following the distribution

234 $N\left(0, \frac{1}{m_{components}}\right)$ where $m_{components}$ represents the number of dimensions to which the data is

235 to be reduced. In cases where the number of feature dimensions is high, the use of random
236 projection can greatly speed up the model training process. In our experiments, the optimal
237 number of components to be kept was determined by the model training step using a grid-search
238 approach. We also enabled the option of using a sparse matrix as the random projection matrix in
239 our package.

240 For dimension reduction, from original R dimension to the reduced r dimension, a very
241 sparse random matrix $\mathbf{Q} \in \mathbb{R}^{r \times R}$ is designed to reduce the computational complexity [67].
242 Specifically, elements of \mathbf{Q} (i.e., $q_{i,j}$) are defined as:

243
$$q_{i,j} = \sqrt{t} \begin{cases} 1 & \text{with probability } \frac{1}{2t} \\ 0 & \text{with probability } 1 - \frac{1}{t}, \text{ where } i = \{1, \dots, r\}, j = \{1, \dots, R\} \\ -1 & \text{with probability } \frac{1}{2t} \end{cases} \quad (9)$$

244 As suggested by [67], we select $t=\sqrt{R}$.

245

246 **Ensemble learning**

247 We use an ensemble learning model in SAMP (**Fig. 3**) where given the training and testing
248 feature matrices \mathbf{M}_{train} and \mathbf{M}_{test} that have been scaled, and whose scaling process will be
249 detailed in the feature scaling session, we first applied random projection on the matrices
250 respectively to get the new feature matrices \mathbf{M}^*_{train} and \mathbf{M}^*_{test} in a lower dimension. We then
251 used the SVM as our base model to train and test on \mathbf{M}^*_{train} and \mathbf{M}^*_{test} respectively. The
252 decision function scores on the testing data are recorded. We repeated the above steps for 10
253 times to stabilize the result of random projection, where randomness is often introduced when
254 generating the random projection matrix. Finally, the decision function scores in each iteration
255 are averaged to get the final scores.

256

257 **Fig. 3 Schematic representation of SAMP workflow.** Benchmarking data consisting of AMPs
258 and non-AMPs were used for training. Features including our proposed proportionalized split
259 amino acid composition (PSAAC) as well as conventional sequence features were constructed.
260 Random projection (RP) was applied multiple times to reduce the feature dimension for
261 robustness. For each RP, the feature matrix was transformed in a low-dimensional space and was
262 then fed into a classification model (here we used a radial basis function (RBF) based support
263 vector machine (SVM) model). The decision scores generated by the RBF-SVM model were

264 integrated by an ensemble learning scheme, based on which predictions for independent test data
265 were made to identify AMPs.

266

267 We then compared and selected the appropriate classifier for AMP sequences classification,
268 including RF, LR, SVM, multilayer perceptron (MLP) and XGBoost. Specifically, SVM is a
269 widely used classification model that allows for the use of different kernel functions to make
270 predictions on both linear and non-linear data. The model is characterized by several parameters,
271 including the regularization parameter (C), the choice of kernel function, and the kernel's gamma
272 parameter (such as Radial Basis Function (RBF)). Random Forest is a powerful ensemble
273 learning method used for both classification and regression tasks. It works by building multiple
274 decision trees and merging their outputs to make predictions. Hyperparameters like n_estimators,
275 max_depth, min_samples_split, min_samples_leaf and bootstrap need to be optimized. Logistic
276 regression makes predictions by modeling the relationship between variables based on
277 logistic/sigmoid function, which is a recognized powerful algorithm used for binary variable
278 classification. Its hyperparameter contains regularization parameter (C), penalty type and solver
279 type. MLP consists at least three layers of notes, including input layer, one/more hidden layers,
280 and an output layer, and it has been used widely for classification and regression analysis. All
281 notes except the input, apply a nonlinear activation function and utilize backpropagation for
282 training. XGBoost is designed for gradient boosting specifically with high performance and
283 scalability, based on the combination of multiple decision trees to create a strong prediction
284 model. It includes the parameter of max_depth, learning_rate and n_estimators. In each iteration
285 of five classifier models, we trained them by performing grid search with repeated 10-fold cross
286 validation to search for the best hyperparameters. Then, the model with the best hyperparameters

287 was used to generate decision function scores for the independent testing datasets. Subsequently,
288 based on the prediction performance, the classifier demonstrating the highest accuracy will be
289 selected to form the foundational architecture of SAMP.

290

291 **Overview of SAMP**

292 SAMP is an ensemble-based model that accurately classifies antimicrobial peptides by
293 averaging the prediction scores from a set of base SVM models. Importantly, SAMP introduces
294 the PSAAC feature, in addition to the widely used numeric features for antimicrobial peptide
295 prediction task proposed in [53]. By implementing the ensemble technique and including a novel
296 feature set, SAMP can excel performance of state-of-the-art approaches.

297 SAMP first encoded the peptide sequence into numeric features, such as AAC, PHYC, and
298 PSAAC (**Fig. 2**). The features were then scaled and projected to a pre-defined lower dimension
299 using random projection technique. Base SVM models were built to generate the prediction
300 scores for each run, which were eventually integrated by an ensemble learning scheme. SAMP
301 was then evaluated on independent test data from four species (including amphibian, bacteria,
302 human, and plant) and compared to other state-of-the-art methods, including iAMPpred and
303 AMPScanner V2. To make fair comparisons, the same training data and independent test data
304 were used to compare SAMP and other state-of-the-art methods.

305 Overall, the PSAAC enables SAMP to capture the peptide sequence information from both
306 the middle region and the N/C-terminus regions, which significantly boosts the model
307 performance in comparison to state-of-the-art methods. In the following sections, we
308 demonstrate the superb performance of SAMP across datasets from different species.

309

310 **Benchmarking with the state-of-the-art methods**

311 We compared the performance of our model with two state-of-the-art methods, iAMPpred
312 and AMPScanner V2. The benchmark test was performed by using the AMP and non-AMP data
313 collected from the dbAMP database. The training data reported in the papers [50,53] for
314 iAMPpred and AMPScanner V2 were obtained to train SAMP separately. To demonstrate the
315 importance of our proposed feature PSAAC and the robustness of our ensemble based SVM
316 model design, we conducted two types of further analyses. First, we trained models both with
317 and without the PSAAC features, evaluating the results to ascertain the importance of PSAAC.
318 Following this, we employed both the ensemble based SVM model design and basic SVM model
319 with one time RP for training and assessed their respective performances. For performance
320 evaluation, we considered four major metrics: accuracy, MCC, G-measure and F1-score. Here,
321 MCC is a measure which produces high score only if the prediction obtained good performance
322 in all four aspects, true and false positives and negatives, of the confusion matrix, making it a
323 reliable rate particularly for imbalanced datasets, as it is not biased toward the majority class [68].
324 The closer the value of MCC is to 1, the better the prediction effect of the classifier is. G-
325 measure is the geometric mean of precision and recall, where the precision is the number of true
326 positive cases divided by the number of all predicted as positive samples, and the recall is the
327 number of true positive results divided by the number of all samples which should be regarded as
328 positive. G-measure effectively balances the extreme ratio of positive to negative instances and
329 the value ranges from 0 to 1, then a value closer to 1, indicating the classifier is performing well
330 in both predicting the positive cases and maintaining accuracy, conversely, a value closer to 0
331 indicates bad performance. F1-score is the harmonic mean of precision and recall, equally
332 weighting the two values. It differs from G-measure in that, F1-score is more sensitive to the

333 extreme values, if there is low precision or recall, the F1-score decreases significantly, however,
334 g-measure will be more tolerant. Similarly, a closer value to 1 means the better prediction ability
335 of the classifier.

336

337 **Results**

338 **Model performance and classifier selection**

339 To enhance the prediction capability of SAMP, we initially selected five ML classifiers,
340 namely SVM, RF, LR, MLP and XGBoost, using the same training and independent test dataset
341 to train and test, then evaluated their performance. We performed 10-fold cross validation for 10
342 times, each time will get an assessment value, as shown in **Fig. 4**, SVM had better performance
343 than LR, MLP, RF and XGBoost, and LR always presents the worst result, based on accuracy,
344 MCC, G-measure and F1-score. Then, five trained classifiers were applied to predict labels for
345 independent test data, as shown in **Fig. 5**, SVM exhibited the highest accuracy, MCC, G-measure
346 and F1-score among all four test datasets. In summary, SVM presents a better performance than
347 RF, MLP, XGBoost and LR, which was determined to serve as the basement of SAMP for
348 further analysis.

349

350 **Fig. 4 Comparing different classifiers for SAMP.** All classifiers were trained on the same
351 dataset collected from iAMPpred to perform 10 times of 10-fold cross validations. Performance
352 measures based on (A) Accuracy, (B) MCC, (C) G-measure, and (D) F1-score were reported.
353 Classifiers include logistic regression (LR), deep learning like multi-layer perceptron (MLP),
354 random forest (RF), SVM (support vector machine), and XGBoost.

355

356 **Fig. 5 Comparison five machine learning models based on independent tests across**
357 **multiple species.** (A) Accuracy, (B) MCC, (C) G-measure, and (D) F1-score were compared
358 across all species including bacteria, human, amphibian, and plant. All models were trained on
359 the dataset collected from [53] and tested on independent test datasets collected from [60].

360

361 We also measured the performance of SAMP across different dimensions of random
362 projection and all the possible proportions of PSAAC (**Table 1**). Specifically, we trained SAMP
363 on the data collected from iAMPpred and AMPScanner V2 respectively. Grid-search with
364 repeated 10-fold cross validation was applied to assess the model performance on training
365 datasets. The number of dimensions used in RP was 50, 100, and 150. Importantly, the novel
366 feature PSAAC enables a customized proportion of information to be obtained from a peptide
367 sequence. To this end, we also evaluated the effect of different proportions of PSAAC on model
368 performance. A given peptide sequence was first split into three parts according to the
369 proportions specified. Next, the amino acid composition within each split was calculated,
370 resulting in a total of 60 new features (see Method). The proportions evaluated include 2:2:6,
371 6:2:2, 2:6:2, and 3:4:3, where, for example, 2:2:6 represents cutting the peptide sequence from
372 the N-terminus for 20% of the total sequence length, another 20% in the middle, and the
373 remaining 60% for the C-terminus.

374

375 **Table 1 Comparing different splitting schemes and reduced dimensions for SAMP.** The
376 splitting scheme means different ratios of the sequence lengths of the N-terminus region, the
377 middle region, and C-terminus region. For example, 2:2:6 means splitting a peptide into three
378 regions as the N-terminus region accounting for 20% of the total sequences, the middle region

379 20%, and the C-terminus region 60%. Here we tried four different splitting schemes including
380 2:2:6, 6:2:2, 2:6:2, and 3:4:3. For reduced dimensions of features, we tried three different cases,
381 50, 100, and 150. ACC, accuracy; MCC, Matthews correlation coefficient; Sn, sensitivity; Sp,
382 specificity; AUC, area under the receiver operating characteristic curve. Numbers in bold
383 represent the best performance for each splitting scheme.

PSAAC	Dimensions	Evaluation Metrics				
		Split	ACC	MCC	Sn	Sp
2:2:6	50	93.04	86.04	91.06	94.92	97.58
	100	93.29	86.24	91.16	95.02	97.79
	150	93.09	86.43	91.57	94.82	97.77
6:2:2	50	93.24	86.28	90.65	95.53	97.63
	100	93.24	86.70	90.75	95.83	97.68
	150	93.29	86.59	90.75	95.73	97.72
2:6:2	50	93.09	86.29	90.55	95.63	97.63
	100	93.60	87.24	91.97	95.22	97.87
	150	93.65	87.35	91.97	95.33	97.82
3:4:3	50	93.65	87.36	91.77	95.53	97.83
	100	93.39	86.85	91.57	95.22	97.89
	150	93.65	87.34	92.07	95.22	97.93

384

385

386

387 As shown in **Table 1**, it presented a comprehensive overview of the SAMP performance
388 under varying ratios of PSAAC with different dimensions. It emphasized how different splitting
389 schemes influenced the performance of SAMP, such as ACC, MCC, Sn, Sp, and AUC. The ACC
390 presented minimum variation, ranging from 93.04 to 93.65 which indicated a consistently good
391 performance across different configurations. The MCC, Sn, Sp and AUC values varied slightly
392 more but still could demonstrate the robust performance of SAMP, with MCC ranging from
393 86.06 to 87.36, Sn from 90.55 to 92.07, Sp from 94.82 to 95.83, and AUC ranging from 97.58 to
394 97.93. Among all the configurations, the 6:2:2 PSAAC ratio reached the highest Sp, while the
395 2:6:2 ratio got the best accuracy and the 3:4:3 ratio outperformed others in terms of ACC, MCC,
396 Sn, and AUC. Analyzing performance based on dimensions, obviously, the dimension of 50 led
397 in ACC and MCC, the dimension of 100 exceeding in Sp, and the dimension of 150 topped in
398 ACC, Sn, and AUC. Therefore, the best model performance was achieved when the proportion
399 was 2:6:2 with feature dimensions reduced to 150 using RP, which indicated the importance of
400 the peptide sequence information from the middle region of peptides.

401

402 **Benchmarking with the state-of-the-art methods**

403 To further evaluate the predictive performance of SAMP, we compared it with the
404 performance of two state-of-the-art AMP prediction tools, iAMPpred and AMPScanner V2. We
405 first retrained SAMP with the same training data from the two methods respectively. We
406 compared their performance by using datasets collected from the dbAMP database. In particular,
407 we chose the AMPs and non-AMPs from plants, bacteria, amphibians, and humans. We
408 considered accuracy, MCC, G-measure and F-1 score as our major evaluation metrics.

409 First, SAMP was trained on 984 AMPs and 984 non-AMPs obtained from the iAMPpred
410 paper. The trained SAMP was tested on the independent dataset from dbAMP. To assess the
411 performance of iAMPpred, we uploaded the independent testing dataset to their web portal
412 (<http://cabgrid.res.in:8080/amppred/>). Similarly, we trained SAMP using the exact same training
413 dataset from AMPScanner V2 and uploaded the testing data to the web portal provided on
414 <https://www.dveltri.com/ascan/v2/ascan.html>. As shown in **Fig. 6**, SAMP demonstrates better
415 performance compared to both iAMPpred and AMPScanner across all four metrics: accuracy,
416 MCC, G-measure and F1-score. When specifically comparing SAMP with iAMPpred (**Fig. 6A**),
417 the most obvious advantage of SAMP is observed in MCC for predicting amphibian labels,
418 where SAMP is 73% more accurate than iAMPpred. On the other hand, the smallest difference is
419 noticed in the F1-score for predicting human labels, with SAMP being 11% more effective than
420 iAMPpred. Notably, all MCC values for iAMPpred are negative, indicating this tool may predict
421 adverse results. Comparing SAMP with AMPScanner (**Fig. 6B**) reveals similar trends. Probably
422 due to a smaller data set in the APD, the largest disparity is seen in Accuracy for human AMP
423 predictions, where SAMP shows a 29% improvement over AMPScanner, whereas the smallest
424 difference is in the G-measure for human predictions, with a small improvement of 8% by
425 SAMP over AMPScanner.

426
427 **Fig. 6 Comparing SAMP with state-of-the-art methods on different species datasets.**
428 Comparing SAMP and iAMPpred across different species in terms of **(A)** Accuracy, **(B)** MCC,
429 **(C)** G-measure and **(D)** F1-score. SAMP was trained on the same training dataset collected from
430 iAMPpred and tested on independent test dataset collected from dbAMP. Comparing SAMP and
431 AMPScanner V2 across different species in terms of **(E)** Accuracy, **(F)** MCC, **(G)** G-measure

432 and (H) F1-score. SAMP was trained on the same training dataset collected from AMPScanner
433 V2 and tested on independent test dataset collected from dbAMP.

434

435 Furthermore, we evaluated the impact of proportionalized split amino acid composition
436 (PSAAC) and the ensemble-based SVM model architecture on the predictive performance (Fig.
437 7). After training with data from iAMPpred, SAMP consistently outperformed both the SAMP
438 without the PSAAC feature and the vanilla SVM model without ensemble learning. This
439 improvement was consistent in all label predictions. Specifically, SAMP demonstrated at least a
440 11% increase in accuracy, 9% in MCC, 5% in G-measure, and 7% in F1-score compared to the
441 situation of deleting the PSAAC feature, and at least a 2% increase in accuracy, 1% in MCC, 1%
442 in G-measure, 1% in F1-score compared to the situation of deleting the layer of ensemble
443 learning. Similar outcomes were observed when trained with AMPScanner data, with SAMP
444 outperforming the aforementioned situations across all measures.

445

446 **Fig. 7 PSAAC and ensemble learning contribute to improving prediction performance of**
447 **SAMP for identifying AMPs.** Comparing SAMP and SAMP without the PSAAC feature across
448 different species in terms of (A) Accuracy, (B) MCC, (C) G-measure and (D) F1-score. All
449 models were trained on the same training dataset collected from iAMPpred and tested on
450 independent test dataset collected from dbAMP. Comparing SAMP and SAMP without ensemble
451 learning across different species in terms of (E) Accuracy, (F) MCC, (G) G-measure and (H) F1-
452 score. All models were trained on the same training dataset collected from AMPScanner V2 and
453 tested on independent test dataset collected from dbAMP.

454

455 **Feature scaling**

456 A crucial step in improving the performance of SVM-based models is feature scaling.
457 Intuitively, if the features are measured in different scales, the decision boundary calculation of
458 SVM would be dominated by the features with the largest scales. In our study, we always scaled
459 the features after the feature generation stage using the *scale* function in R. In particular, the
460 peptide sequence features are calculated in different scales. For example, the amino acid
461 composition is measured as some values between 0 and 1, but certain physio-chemical properties
462 such as hydrophobicity can have various ranges of value. We believe this step is essential for
463 SAMP to make accurate predictions and is worth experimenting. We generated two sets of
464 features from the peptide sequences used to train iAMPpred, in which one set of features was
465 scaled and the other was not. Two separate SAMP models were trained and evaluated on the
466 independent test datasets. Our results indicate that scaling is indeed extremely important for
467 SAMP, consistently boosting the model performance by a least 50% across datasets (**Table 2**).
468

469 **Table 2 Scaling the features is crucial for SAMP for identifying AMPs.** The scaling is
470 performed by subtracting the mean of each feature and dividing by the feature's standard
471 deviation. Scaling is a crucial step for SAMP. ACC, accuracy; MCC, Matthews correlation
472 coefficient; AUC, area under the receiver operating characteristic curve.

Dataset	Metric	SAMP (Scaled)	SAMP (No Scale)
dbAMP Plant	Accuracy	0.668	0.102
	AUC	0.744	0.112
	MCC	0.332	-0.184
dbAMP Bacteria	Accuracy	0.647	0.071

	AUC	0.703	0.088
	MCC	0.234	-0.165
dbAMP Amphibian	Accuracy	0.779	0.336
	AUC	0.844	0.039
	MCC	0.624	-0.169
dbAMP Human	Accuracy	0.637	0.058
	AUC	0.712	0.137
	MCC	0.204	-0.2

473

474

475

476 Discussion

477 AMPs have gained greater attention as an alternative to chemical antibiotics. Indeed, some
478 are already in applications either as antibiotics or as food preservatives [69]. Computational
479 methods are developed as a supplement for wet lab experiments to design and identify AMPs,
480 which reduces the cost and resources required. In this study, we present a novel ensemble-based
481 model that achieves better AMP prediction performance than existing, state-of-the-art methods.
482 To the best of our knowledge, SAMP is the first method that adopts PSAAC as one of the
483 numeric features for AMP prediction tasks. Amino acid compositional splitting sheds new light
484 on amino acid compositions of natural AMPs, which was initially discovered in 2009 [70]. In
485 natural AMPs, alanine, glycine, leucine, and lysine are frequently occurring (or abundant) amino
486 acids, while histidine, methionine, and tryptophan are least abundant amino acids. Our sequence
487 splitting here reveals that leucine is preferentially dominant at the N-terminus of AMPs, while
488 alanine is mainly located at the middle region. Glycine can appear frequently both at the N and

489 the middle regions. In contrast, lysine is primarily abundant in the middle and C-terminus of
490 natural AMPs. Interestingly after sequence splitting, the least abundant methionine and
491 tryptophan appear mainly at the middle and the C-terminus regions, whereas histidine occupies
492 the N-terminus. Also of note is that acidic glutamic acid is located at the N-terminus and acidic
493 aspartic acid prefers the C-terminus region.

494 By combining this novel sequence-splitting feature with an ensemble-based SVM model
495 architecture, SAMP is able to maximally extract peptide sequence information and outperform
496 methods that apply either deep learning or traditional machine learning techniques. Additionally,
497 we developed SAMP based on RP, a powerful dimension-reduction algorithm based on the
498 Johnson–Lindenstrauss lemma [66] which can preserve the distances between data points while
499 reducing the dimension [71]. As the number of data points continues to grow, the accuracy of
500 prediction may be influenced due to the low efficiency of computational efficiency. Therefore,
501 RP based models should have better performance compared to those without it. This has been
502 evidenced in a large-scale single-cell RNA-sequencing (scRNA-seq) data processed algorithm
503 which showed a higher classification efficiency under the contribution of ensemble RP layer [72].
504 As expected, our model with the ensemble RP layer also has a better performance as shown in
505 **Fig. 7**. Our prediction also implies that data size influences prediction performance since the
506 human AMPs, with the least data (<150 AMPs in the current APD), behave poorest compared to
507 AMPs from bacteria, plants, and animals with more known positive data.

508 We also assessed the performance of SAMP with specific tools, like iAMPpred and
509 AMPScanner V2, which are also designed for AMP prediction based on SVM and DNN
510 respectively. SAMP proved slightly better performance than AMPScanner V2 and obviously
511 higher accuracy than iAMPpred. Possible explanation for this discrepancy should be the

512 omission of PSAAC and ensemble RP layer. Overall, this newly designed tool, SAMP, is
513 expected to compensate for the existing tools for AMP prediction.

514 For future research directions, we will consider different ensemble methods by including
515 more diverse model categories to improve the prediction accuracy. With the advance of deep
516 learning, it would be appealing to investigate the performance of DL based models combined
517 with PSAAC features, or whether the deep neural networks are able to capture the PSAAC
518 features within their embedding space.

519 **Key points**

520 We propose a novel method called SAMP that develops a new type of features called
521 proportionalized split amino acid composition (PSAAC) to significantly boost the performance
522 of identifying antimicrobial peptides.

523

524 PSAAC can identify residue patterns at both the N-terminus and the C-terminus as well as to
525 retain sequence order information from the middle region of peptide fragments.

526

527 SAMP leverages an ensemble learning framework based on random projection to integrate
528 various classifiers into a cohesive framework, effectively improving the performance accuracy.

529

530 SAMP outperforms state-of-the-art methods for AMP identification in terms of accuracy, G-
531 measure, MCC and F1-score.

532

533 SAMP is a versatile tool capable of identifying AMPs from a variety of organisms including
534 human, plant, bacteria and amphibian.

535

536 **Competing interests**

537 The authors declare no competing interests.

538

539 **Supplementary Data**

540 **Supplementary Fig. S1**

541 **Amino acid distribution in AMPs and non-AMPs datasets based on the dataset collected**
542 **from AMPScanner V2.** Amino acid distribution of all sequences in (A) AMPs and (B) non-
543 AMPs dataset. Distribution of amino acid sequences in the N-terminus region, the middle region
544 and the C-terminus region of (C) AMPs Dataset and (D) non-AMPs dataset.

545

546 **Supplementary Fig. S2**

547 **Amino acid distribution in AMPs and non-AMPs datasets based on the dataset collected**
548 **from dbAMP.** Amino acid distribution of all sequences in (A) AMPs and (B) non-AMPs dataset.
549 Distribution of amino acid sequences in the N-terminus region, the middle region and the C-
550 terminus region of (C) AMPs Dataset and (D) non-AMPs dataset.

551

552 **Funding**

553 The research reported in this publication was supported by the National Cancer Institute of the
554 National Institutes of Health under Award Number P30CA036727. This work was supported by
555 the American Cancer Society under award number IRG-22-146-07-IRG and by the Buffett
556 Cancer Center, which is supported by the National Cancer Institute under award number
557 CA036727. This work was supported by the Buffet Cancer Center, which is supported by the
558 National Cancer Institute under award number CA036727, in collaboration with the
559 UNMC/Children's Hospital & Medical Center Child Health Research Institute Pediatric Cancer
560 Research Group. This study was supported, in part, by the National Institute on Alcohol Abuse
561 and Alcoholism (P50AA030407-5126, Pilot Core grant). This study was also supported by the
562 Nebraska EPSCoR FIRST Award (OIA-2044049). This work was also partially supported by the
563 National Institute of General Medical Sciences under Award Number P20GM130447. The

564 content is solely the responsibility of the authors and does not necessarily represent the official
565 views from the funding organizations.

566

567 **Authors' contributions**

568 SW conceived and designed the study. JF and MS developed the algorithm, performed the
569 experiments and analyzed the data. JF implemented the SAMP package. All authors participated
570 in writing the paper. The manuscript was approved by all authors.

571

572 **Data availability**

573 All the data used in this manuscript are publicly available in the corresponding references.

574 **Reference**

- 575 1. Mishra NN, Bayer AS. Correlation of Cell Membrane Lipid Profiles with Daptomycin
576 Resistance in Methicillin-Resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2013;
577 57:1082–1085
- 578 2. Fernandes P. Antibacterial discovery and development—the failure of success? *Nature*
579 *biotechnology* 2006; 24:1497–1503
- 580 3. Adedeji WA. THE TREASURE CALLED ANTIBIOTICS. *Ann Ib Postgrad Med* 2016;
581 14:56–57
- 582 4. Thomas L. The youngest science: notes of a medicine-watcher. 1995;
- 583 5. Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future.
584 *Frontiers in microbiology* 2010; 1:134
- 585 6. Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. *Current*
586 *opinion in microbiology* 2019; 51:72–80
- 587 7. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted
588 phenomenon. *Pathogens and global health* 2015; 109:309–318
- 589 8. De Oliveira DM, Forde BM, Kidd TJ, et al. Antimicrobial resistance in ESKAPE pathogens.
590 *Clinical microbiology reviews* 2020; 33:10.1128/cmr. 00181-19
- 591 9. Huemer M, Mairpady Shambat S, Brugger SD, et al. Antibiotic resistance and persistence—
592 Implications for human health and treatment perspectives. *EMBO reports* 2020; 21:e51034
- 593 10. Frieri M, Kumar K, Boutin A. Antibiotic resistance. *Journal of infection and public health*
594 2017; 10:369–378
- 595 11. Lei J, Sun L, Huang S, et al. The antimicrobial peptides and their potential clinical
596 applications. *American journal of translational research* 2019; 11:3919
- 597 12. Kadri SS. Key takeaways from the US CDC’s 2019 antibiotic resistance threats report for
598 frontline providers. *Critical care medicine* 2020; 48:939–945
- 599 13. de Kraker MEA, Stewardson AJ, Harbarth S. Will 10 Million People Die a Year due to
600 Antimicrobial Resistance by 2050? *PLoS Med* 2016; 13:e1002184
- 601 14. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations.
602 2016;
- 603 15. Kang X, Dong F, Shi C, et al. DRAMP 2.0, an updated data repository of antimicrobial
604 peptides. *Scientific data* 2019; 6:148
- 605 16. Chen CH, Lu TK. Development and challenges of antimicrobial peptides for therapeutic
606 applications. *Antibiotics* 2020; 9:24
- 607 17. Mookherjee N, Anderson MA, Haagsman HP, et al. Antimicrobial host defence peptides:
608 functions and clinical potential. *Nature reviews Drug discovery* 2020; 19:311–332
- 609 18. Diamond G, Beckloff N, Weinberg A, et al. The roles of antimicrobial peptides in innate
610 host defense. *Current pharmaceutical design* 2009; 15:2377–2392
- 611 19. Wang G, Li X, Wang Z. APD3: the antimicrobial peptide database as a tool for research and
612 education. *Nucleic Acids Res* 2016; 44:D1087–D1093
- 613 20. Hiemstra PS, Amatngalim GD, Van Der Does AM, et al. Antimicrobial Peptides and Innate
614 Lung Defenses. *Chest* 2016; 149:545–551
- 615 21. Silva ON, De La Fuente-Núñez C, Haney EF, et al. An anti-infective synthetic peptide with
616 dual antimicrobial and immunomodulatory activities. *Scientific reports* 2016; 6:35465

617 22. Frohm M, Agerberth B, Ahangari G, et al. The expression of the gene coding for the
618 antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders.
619 *Journal of Biological Chemistry* 1997; 272:15258–15263

620 23. Liang W, Diana J. The dual role of antimicrobial peptides in autoimmunity. *Frontiers in*
621 *immunology* 2020; 11:545577

622 24. De La Fuente-Núñez C, Silva ON, Lu TK, et al. Antimicrobial peptides: Role in human
623 disease and potential as immunotherapies. *Pharmacology & Therapeutics* 2017; 178:132–140

624 25. Li C, Zhu C, Ren B, et al. Two optimized antimicrobial peptides with therapeutic potential
625 for clinical antibiotic-resistant *Staphylococcus aureus*. *European journal of medicinal chemistry*
626 2019; 183:111686

627 26. Fan L, Wei Y, Chen Y, et al. Epinecidin-1, a marine antifungal peptide, inhibits *Botrytis*
628 *cinerea* and delays gray mold in postharvest peaches. *Food Chemistry* 2023; 403:134419

629 27. Adade CM, Oliveira IR, Pais JA, et al. Melittin peptide kills *Trypanosoma cruzi* parasites
630 by inducing different cell death pathways. *Toxicon* 2013; 69:227–239

631 28. Huan Y, Kong Q, Mou H, et al. Antimicrobial peptides: classification, design, application
632 and research progress in multiple fields. *Frontiers in microbiology* 2020; 11:582779

633 29. Wachinger M, Kleinschmidt A, Winder D, et al. Antimicrobial peptides melittin and
634 cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene
635 expression. *Journal of General Virology* 1998; 79:731–740

636 30. Torres MD, Cao J, Franco OL, et al. Synthetic biology and computer-based frameworks for
637 antimicrobial peptide discovery. *ACS nano* 2021; 15:2143–2164

638 31. Li J, Koh J-J, Liu S, et al. Membrane active antimicrobial peptides: translating mechanistic
639 insights to design. *Frontiers in neuroscience* 2017; 11:244777

640 32. Travkova OG, Moehwald H, Brezesinski G. The interaction of antimicrobial peptides with
641 membranes. *Advances in colloid and interface science* 2017; 247:521–532

642 33. Kumar P, Kizhakkedathu JN, Straus SK. Antimicrobial peptides: diversity, mechanism of
643 action and strategies to improve the activity and biocompatibility in vivo. *Biomolecules* 2018;
644 8:4

645 34. Ahmed TA, Hammami R. Recent insights into structure–function relationships of
646 antimicrobial peptides. *Journal of food biochemistry* 2019; 43:e12546

647 35. Le C-F, Fang C-M, Sekaran SD. Intracellular targeting mechanisms by antimicrobial
648 peptides. *Antimicrobial agents and chemotherapy* 2017; 61:10.1128/aac. 02340-16

649 36. Li S, Wang Y, Xue Z, et al. The structure-mechanism relationship and mode of actions of
650 antimicrobial peptides: A review. *Trends in Food Science & Technology* 2021; 109:103–115

651 37. Andersson DI, Hughes D, Kubicek-Sutherland JZ. Mechanisms and consequences of
652 bacterial resistance to antimicrobial peptides. *Drug Resistance Updates* 2016; 26:43–57

653 38. Lázár V, Martins A, Spohn R, et al. Antibiotic-resistant bacteria show widespread collateral
654 sensitivity to antimicrobial peptides. *Nature microbiology* 2018; 3:718–731

655 39. Spohn R, Daruka L, Lázár V, et al. Integrated evolutionary analysis reveals antimicrobial
656 peptides with limited resistance. *Nature communications* 2019; 10:4538

657 40. Cortes C, Vapnik V. Support-vector networks. *Machine learning* 1995; 20:273–297

658 41. Breiman L. Random forests. *Machine learning* 2001; 45:5–32

659 42. Tolles J, Meurer WJ. Logistic regression: relating patient characteristics to outcomes. *Jama*
660 2016; 316:533–534

661 43. Wang G, Vaisman II, Van Hoek ML. Machine Learning Prediction of Antimicrobial
662 Peptides. *Computational Peptide Science* 2022; 2405:1–37

663 44. Huang J, Xu Y, Xue Y, et al. Identification of potent antimicrobial peptides via a machine-
664 learning pipeline that mines the entire space of peptide sequences. *Nature Biomedical
665 Engineering* 2023; 7:797–810

666 45. Chen T, Guestrin C. Xgboost: A scalable tree boosting system. *Proceedings of the 22nd
667 acm sigkdd international conference on knowledge discovery and data mining* 2016; 785–794

668 46. LeCun Y, Bottou L, Bengio Y, et al. Gradient-based learning applied to document
669 recognition. *Proceedings of the IEEE* 1998; 86:2278–2324

670 47. Hochreiter S, Schmidhuber J. Long short-term memory. *Neural computation* 1997; 9:1735–
671 1780

672 48. Ma Y, Guo Z, Xia B, et al. Identification of antimicrobial peptides from the human gut
673 microbiome using deep learning. *Nature Biotechnology* 2022; 40:921–931

674 49. Devlin J, Chang M-W, Lee K, et al. Bert: Pre-training of deep bidirectional transformers for
675 language understanding. *arXiv preprint arXiv:1810.04805* 2018;

676 50. Veltri D, Kamath U, Shehu A. Deep learning improves antimicrobial peptide recognition.
677 *Bioinformatics* 2018; 34:2740–2747

678 51. Yan J, Bhadra P, Li A, et al. Deep-AmPEP30: improve short antimicrobial peptides
679 prediction with deep learning. *Molecular Therapy-Nucleic Acids* 2020; 20:882–894

680 52. Lee KJ. Architecture of neural processing unit for deep neural networks. *Advances in
681 Computers* 2021; 122:217–245

682 53. Meher PK, Sahu TK, Saini V, et al. Predicting antimicrobial peptides with improved
683 accuracy by incorporating the compositional, physico-chemical and structural features into
684 Chou's general PseAAC. *Sci Rep* 2017; 7:42362

685 54. García-Jacas CR, Pinacho-Castellanos SA, García-González LA, et al. Do deep learning
686 models make a difference in the identification of antimicrobial peptides? *Briefings in
687 Bioinformatics* 2022; 23:bbac094

688 55. Bingham E, Mannila H. Random projection in dimensionality reduction: applications to
689 image and text data. *Proceedings of the seventh ACM SIGKDD international conference on
690 Knowledge discovery and data mining* 2001; 245–250

691 56. Wan S, Mak M-W, Kung S-Y. Ensemble linear neighborhood propagation for predicting
692 subchloroplast localization of multi-location proteins. *Journal of proteome research* 2016;
693 15:4755–4762

694 57. Wang Z. APD: the Antimicrobial Peptide Database. *Nucleic Acids Research* 2004; 32:590D
695 – 592

696 58. Wang G. The antimicrobial peptide database is 20 years old: Recent developments and
697 future directions. *Protein Science* 2023; 32:e4778

698 59. Lata S, Sharma B, Raghava G. Analysis and prediction of antibacterial peptides. *BMC
699 Bioinformatics* 2007; 8:263

700 60. Jhong J-H, Yao L, Pang Y, et al. dbAMP 2.0: updated resource for antimicrobial peptides
701 with an enhanced scanning method for genomic and proteomic data. *Nucleic acids research* 2022;
702 50:D460–D470

703 61. Osorio D, Rondón-Villarreal P, Torres R. Peptides: a package for data mining of
704 antimicrobial peptides. *Small* 2015; 12:44–444

705 62. Verma R, Varshney GC, Raghava GPS. Prediction of mitochondrial proteins of malaria
706 parasite using split amino acid composition and PSSM profile. *Amino Acids* 2010; 39:101–110

707 63. Hayat M, Khan A, Yeasin M. Prediction of membrane proteins using split amino acid and
708 ensemble classification. *Amino acids* 2012; 42:2447–2460

709 64. Nakai K. Protein sorting signals and prediction of subcellular localization. *Advances in*
710 *protein chemistry* 2000; 54:277–344

711 65. Emanuelsson O. Predicting protein subcellular localisation from amino acid sequence
712 information. *Briefings in bioinformatics* 2002; 3:361–376

713 66. Johnson WB, Lindenstrauss J, Schechtman G. Extensions of Lipschitz maps into Banach
714 spaces. *Israel Journal of Mathematics* 1986; 54:129–138

715 67. Li P, Hastie TJ, Church KW. Very sparse random projections. *Proceedings of the 12th*
716 *ACM SIGKDD international conference on Knowledge discovery and data mining* 2006; 287–
717 296

718 68. Chicco D, Jurman G. The advantages of the Matthews correlation coefficient (MCC) over
719 F1 score and accuracy in binary classification evaluation. *BMC genomics* 2020; 21:1–13










720 69. Mishra B, Reiling S, Zarena D, et al. Host defense antimicrobial peptides as antibiotics:
721 design and application strategies. *Current opinion in chemical biology* 2017; 38:87–96

722 70. Wang G, Li X, Wang Z. APD2: the updated antimicrobial peptide database and its
723 application in peptide design. *Nucleic Acids Research* 2009; 37:D933–D937

724 71. Frankl P, Maehara H. The Johnson-Lindenstrauss lemma and the sphericity of some graphs.
725 *Journal of Combinatorial Theory, Series B* 1988; 44:355–362




726 72. Wan S, Kim J, Won KJ. SHARP: hyperfast and accurate processing of single-cell RNA-seq
727 data via ensemble random projection. *Genome Res.* 2020; 30:205–213

728

A**B****C****D****E****F****G****H****I**

Type

AMP	Red
non-AMP	Teal

A Amino Acid Distribution for the AMPs Data**B Amino Acid Distribution for the Non-AMPs Data****C Amino Acid Distribution in N-terminus, Middle and C-terminus Regions for the AMPs Data****D Amino Acid Distribution in N-terminus, Middle and C-terminus Regions for the Non-AMPs Data**